Abiraterone Tosylate Impurity
● Under Development
| Catalogue No.: | VL830050 |
|---|---|
| CAS No.: | N/A |
| Mol. Formula: | C31H37NO3S |
| Mol. Weight: | 503.7 g/mol |
Additional information on Abiraterone Tosylate Impurity
Parent drug
AbirateroneIUPAC Name
(3S, 8R, 9S, 10R, 13S, 14S)-10, 13-Dimethyl-17-(pyridin-3-yl)-2, 3, 4, 7, 8, 9, 10, 11, 12, 13, 14, 15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl 4-methylbenzenesulfonatePharmacopoeial Synonyms
N/AOther Synonyms
N/ASmiles
O=S(C1=CC=C(C)C=C1)(O[C@H]2CC[C@]3(C)[C@@]4([H])CC[C@]5(C)C(C6=CC=CN=C6)=CC[C@@]5([H])[C@]4([H])CC=C3C2)=OInChI
InChI=1S/C31H37NO3S/c1-21-6-9-25(10-7-21)36(33,34)35-24-14-16-30(2)23(19-24)8-11-26-28-13-12-27(22-5-4-18-32-20-22)31(28,3)17-15-29(26)30/h4-10,12,18,20,24,26,28-29H,11,13-17,19H2,1-3H3/t24-,26-,28-,29-,30-,31+/m0/s1Description
The compound Abiraterone Tosylate Impurity is a thoroughly characterized reference standard that complies with rigorous regulatory guidelines, including those from USP, EMA, JP, and BP. It is ideal for critical applications such as analytical method development, method validation (AMV), and quality control (QC), especially in the production of Abiraterone. Designed to support both Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA), this product delivers the precision required for reliable results. Additionally, it includes a detailed Structure Elucidation Report (SER), ensuring accuracy and dependability for advanced analytical purposes. Abiraterone Tosylate Impurity is an intermediate formed during the synthesis of abiraterone is an Inhibitor of preandrogen enzyme that blocks androgen synthesis and is suitable for pharmacological treatment of disorders of preandrogen that is extremely active in both testes and adrenals.
References
Kiss, Anita, et al. “Synthesis of Novel 17-Triazolyl-Androst-5-En-3-Ol Epimers via Cu(I)-Catalyzed Azide-Alkyne Cycloaddition and Their Inhibitory Effect on 17a-Hydroxylase/c 17, 20 -Lyase.†Steroids, vol. 135, July 2018, pp. 79–91, https://doi.org/10.1016/j.steroids.2018.03.006. ?Request a Quote
"*" indicates required fields









